<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Fertil Steril</journal-id><journal-id journal-id-type="iso-abbrev">Int J Fertil Steril</journal-id><journal-id journal-id-type="publisher-id">Royan Institute</journal-id><journal-title-group><journal-title>International Journal of Fertility &#x00026; Sterility</journal-title></journal-title-group><issn pub-type="ppub">2008-076X</issn><issn pub-type="epub">2008-0778</issn><publisher><publisher-name>Royan Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24520450</article-id><article-id pub-id-type="pmc">3850311</article-id><article-id pub-id-type="other">Int-J-Fertil-Steril-6-266</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group><subject>ART</subject><subject>Gynecology and Female Infertility</subject></subj-group></subj-group></article-categories><title-group><article-title>Microdose GnRH Agonist Flare-Up versus Ultrashort GnRH Agonist
Combined with Fixed GnRH Antagonist in Poor Responders of
Assisted Reproductive Techniques Cycles</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Eftekhar</surname><given-names>Maryam</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mohammadian</surname><given-names>Farnaz</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yousefnejad</surname><given-names>Fariba</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Khani</surname><given-names>Parisa</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="A3">3</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff id="A1"><label>1</label>Department of Obstetrics and Gynecology, Research and Clinical Center for Infertility, Shahid Sadoughi University of
Medical Sciences, Yazd, Iran</aff><aff id="A2"><label>2</label>Department of Obstetrics and Gynecology, Zanjan University of Medical Sciences, Zanjan, Iran</aff><aff id="A3"><label>3</label>Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</aff></contrib-group><author-notes><corresp id="cor1">
* Corresponding Address:
<addr-line>P.O.Box: 89195999</addr-line><addr-line>Research and Clinical
Center for Infertility</addr-line><institution>Shahid Sadoughi University of Medical Sciences</institution><addr-line>Yazd</addr-line><country>Iran</country>
Email: <email>pkhani55@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2013</year></pub-date><pub-date pub-type="epub"><day>3</day><month>3</month><year>2013</year></pub-date><volume>6</volume><issue>4</issue><fpage>266</fpage><lpage>271</lpage><history><date date-type="received"><day>16</day><month>10</month><year>2011</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>This study compares the microdose flare-up protocol to the ultrashort gonadotropinreleasing
hormone (GnRH) agonist flare combined with the fixed multidose GnRH antagonist
protocol in poor responders undergoing ovarian stimulation.</p></sec><sec><title>Materials and Methods:</title><p>In this randomized clinical trial, 120 women who were candidates for
assisted reproductive techniques (ART) and had histories of one or more failed <italic>in vitro</italic> fertilization
(IVF) cycles with three or fewer retrieved oocytes were prospectively randomized into two groups.
Group I (60 patients) received the microdose flare-up regimen and group II (60 patients) received
the ultrashort GnRH agonist combined with fixed GnRH antagonist.</p></sec><sec><title>Results:</title><p>There were no significant differences between the groups in the number of used gonadotropin
ampoules (p=0.591), duration of stimulation (p=0.610), number of retrieved oocytes (p=0.802),
fertilization rate (p=0.456), and the number of transferred embryos (p=0.954). The clinical pregnancy
rates were statistically similar in group I (10%) compared with group II (13.3%, p=0.389).</p></sec><sec><title>Conclusion:</title><p>According to our results, there is no significant difference between these protocols
for improving the ART outcome in poor responders. Additional prospective, randomized
studies with more patients is necessary to determine the best protocol (Registration Number:
IRCT201105096420N1).</p></sec></abstract><kwd-group><kwd>GnRH Agonist</kwd><kwd>GnRH Antagonist</kwd><kwd>Poor Responder</kwd><kwd>Assisted Reproductive Technology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>Citation</meta-name><meta-value>Eftekhar M, Mohammadian F, Yousefnejad F, Khani P. Microdose GnRH agonist Flare-Up versus ultrashort GnRH agonist combined
with fixed GnRH antagonist in poor responders of assisted reproductive techniques cycles. Int J Fertil Steril. 2013; 6(4): 266-271.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><title>Introduction</title><p>Despite considerable advancements over the past
decade in assisted reproduction, poor responders remain
an important challenge. These patients have more
problems in fertilization, embryo quality, and pregnancy.
Poor response to ovarian stimulation occurs in
9-18% of assisted reproductive technique (ART) cycles.
However there is no specific definition for poor
responders, thus a comparison of outcomes from various
protocols is challenging (<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref>). The most common
definition of a poor responder is based on increased basal
FSH, an inadequate ovarian response, low oestradiol
(E2) levels to ovarian stimulation by FSH/HMG,
and lower number of retrieved oocytes (<xref rid="B3" ref-type="bibr">3</xref>-<xref rid="B6" ref-type="bibr">6</xref>).</p><p>Several strategies are available to improve ovarian
stimulation outcome in poor responders, including
increase the dose of the gonatropin that
is being used and administration of gonadotropinreleasing
hormone (GnRH) analogs (agonists or
antagonists). The use of clomiphene citrate, aromatase
inhibitors, growth hormones, transdermal
testosterone, corticosteroids, estradiol or aspirin are recommended as adjuvant therapies (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B7" ref-type="bibr">7</xref>-<xref rid="B10" ref-type="bibr">10</xref>).</p><p>One of the most successful protocols for ovarian
stimulation of poor responders is the microdose flareup
protocol (<xref rid="B11" ref-type="bibr">11</xref>-<xref rid="B13" ref-type="bibr">13</xref>). The basic hypothesis of this approach
involves administration of a minimal dose of
GnRH-a to stimulate gonadotropin release and minimize
premature ovulation (<xref rid="B14" ref-type="bibr">14</xref>). GnRH antagonists
represent an alternative in the management of poor responders
(<xref rid="B15" ref-type="bibr">15</xref>). Antagonists act to rapidly block gonadotropin
receptors so ovarian stimulation can be initiated
before administration of the GnRH antagonist. As
a result these agents prevent a premature LH surge but
do not suppress early follicular development (<xref rid="B16" ref-type="bibr">16</xref>-<xref rid="B18" ref-type="bibr">18</xref>).
GnRH antagonists have no flair effect on follicular development
compare with GnRH agonists.</p><p>Our hypothesis is to compare the microdose Gn-
RH-a flare-up protocol with the combined stimulatory
effect of GnRH agonists and immediate suppression
of the GnRH antagonist in a unique protocol that
may be a valuable new strategy for ovarian stimulation
of poor responders, causing an improved ART
outcome. In this study we compare the microdose
flare-up protocol to the ultrashort GnRH agonist flare
combined with the fixed multidose GnRH antagonist
protocol in poor responders undergoing ART cycles.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Patients</title><p>
A total of 120 poor responder women who referred
to the Yazd Fertility and Infertility Center of
Shahid Sadoughi University of Medical Sciences
from June 2007 to July 2009 were enrolled in this
randomized clinical trial. This randomized, controlled
study was approved by the Ethics Committee
of Yazd Fertility and Infertility Center and was
undertaken in accordance with CONSORT guidelines
(<xref ref-type="fig" rid="F1">Fig 1</xref>). All patients signed a written consent
form before initiation of the treatment cycles.</p><p>All included patients had a history of one or more
failed IVF cycles with three or less retrieved oocytes.
There was no age limitation for participants. We excluded
patients with: 1. body mass index (BMI) &#x0003e;30,
2. endocrine or metabolic disorders, 3. history of endometriosis
or 4.severe male factor (azspermia).</p><p>Patients were randomly allocated into two groups by
the use of sealed envelopes. In group I (60 patients)
the microdose flare-up regimen was used. Group II (60
patients) were treated with the ultrashort GnRH agonist
combined with fixed GnRH antagonist regimens.</p></sec><sec><title>Ovarian stimulation protocols</title><p>
All patients received oral contraceptive pills during
their previous menstrual cycle. In group I patients
received 0.05 mg subcutaneous buserelin
(Suprefact, Serono) injections twice daily from the
first day of the cycle that continued until the day of
the HCG injection. Ovarian stimulation was started
from the third day of the patient,s menstrual cycle
by intramuscular (IM) injections of HMG (Menogon,
Ferring, Germany) at a dose of 300 IU per day.
Follicular monitoring began from the ninth day of
the cycle by serial vaginal ultrasonography and
measurement of serum E2 levels. I.M. injections of
10000 IU HCG (Pregnyl; NV Organon, Oss, The
Netherlands) were injected when at least 2 follicles
&#x02265;18 mm were observed on ultrasonography.</p><p>Group II patients received buserelin (Suprefact, Serono),
0.5 mg/ subcutaneous (SC) per day from the first
day of the menstrual cycle, which was continued for
three consecutive days. HMG (Menogon, Ferring) at
300 IU per day was started on day three of the cycle.
The GnRH antagonist (Cetrorelix, Serono Laboratories,
Aubonne, Switzerland) at a dose of 0.25 mg SC per day
was started when the dominant follicle size reached a
diameter of 14 mm. Follicular monitoring by vaginal
ultrasonography and estradiol level measurement began
on the ninth day of the cycle. Patients received 10000 IU
HCG (Pregnyle, NV Organon, Oss, The Netherlands)
when at least 2 follicles that were &#x02265;17-18 mm in diameter
were observed by ultrasonography. In both groups
oocyte retrieval was performed 34-36 hours after the
HCG injection, using a 17 gauge needle under vaginal
ultrasonography guidance. Conventional IVF or intracytoplasmic
sperm injection (ICSI) was appropriately
performed. Fertilization rate was defined as the ratio
of number of oocytes with pronuclei observed at least
18 hours after IVF or ICSI to the number of retrieved
oocytes. A Labotect catheter (Labotect, Gottingen Germany)
was used to transfer the embryos at 48-72 hours
following oocyte retrieval. Luteal phase support began
with I.M. injections of progesterone in oil (progesterone,
Aburaihan Co., Tehran, Iran) at a dose of 100 mg daily
on the day of oocyte retrieval and continued until documentation
of fetal heart activity by ultrasound. Primary
outcome was the clinical pregnancy rate per cycle.</p><p>Clinical pregnancy was identified as observation
of fetal heart activity by transvaginal ultrasonography
performed three weeks after a
positive &#x003b2;-hCGv (&#x003b2;-hCG &#x0003e;50 IU/L) two weeks
after embryo transfer. This means that the ultrasonography
was actually 5 weeks after embryo
transfer.</p><fig id="F1" orientation="portrait" position="float"><label>Fig 1</label><caption><p>Study flowchart</p></caption><graphic xlink:href="Int-J-Fertil-Steril-6-266-g01"/></fig></sec><sec><title>Statistical analysis</title><p>
The Statistical Package for Social Sciences
(SPSS, version 15.0 for Windows; SPSS Inc., Chicago,
IL) was used for data analysis. Student&#x02019;s ttest
and chi-square test were used to detect significant
difference (p&#x0003c;0.05) between the variables. All
data were expressed as mean &#x000b1; SD.</p></sec></sec><sec sec-type="results"><title>Results</title><p>We randomly recruited 120 patients, with 60 patients
in each treatment group. There were no significant
differences in mean female age, basal FSH
and duration of infertility between both groups (<xref ref-type="table" rid="T1">Table 1</xref>). After randomization, 6 patients in group I did
not have embryo transfers. Of these, 2 patients had
no oocytes in oocyte retrieval and 4 had fertilization
failure. In group II, 5 patients did not have embryo
transfers, of which 1 patient had no response
to ovarian stimulation, 1 patient had no oocytes
obtained during oocyte retrieval, and 3 patients had
fertilization failure. All 11 patients were part of the
final analysis and not excluded from the study. There
were no patients lost to follow up. Table 2 shows the
cycle characteristics and ART outcomes.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patient&#x02019;s characteristic in two groups (Mean &#x000b1; SD)</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Microdose flare-up</th><th rowspan="1" colspan="1">GnRH agonist/antagonist</th><th rowspan="1" colspan="1">P value</th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Female age (Y)</bold></td><td rowspan="1" colspan="1">33.31 &#x000b1; 6.02</td><td rowspan="1" colspan="1">35.33 &#x000b1; 4.11</td><td rowspan="1" colspan="1">0.139</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Infertility duration (Y)</bold></td><td rowspan="1" colspan="1">9.91 &#x000b1; 5.10</td><td rowspan="1" colspan="1">8.00 &#x000b1; 5.32</td><td rowspan="1" colspan="1">0.310</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Basal FSH (mIU/ml)</bold></td><td rowspan="1" colspan="1">9.43 &#x000b1; 2.11</td><td rowspan="1" colspan="1">9.91 &#x000b1; 1.90</td><td rowspan="1" colspan="1">0.315</td></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>ART outcome in two groups (Mean &#x000b1; SD)</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">P value</th><th rowspan="1" colspan="1">GnRH agonist/ antagonist</th><th rowspan="1" colspan="1">Microdose flare-up</th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><td align="left" rowspan="1" colspan="1"><bold>No. of used gonadotropin ampoules</bold></td><td rowspan="1" colspan="1">0.591</td><td rowspan="1" colspan="1">44.12 &#x000b1; 8.20</td><td rowspan="1" colspan="1">45.20 &#x000b1; 6.93</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Duration of stimulation (Days)</bold></td><td rowspan="1" colspan="1">0.610</td><td rowspan="1" colspan="1">11.60 &#x000b1; 1.32</td><td rowspan="1" colspan="1">11.42 &#x000b1; 1.61</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>No. of retrieved oocytes</bold></td><td rowspan="1" colspan="1">0.802</td><td rowspan="1" colspan="1">4.61&#x000b1; 3.53</td><td rowspan="1" colspan="1">4.42 &#x000b1; 3.63</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>No. of transferred embryos</bold></td><td rowspan="1" colspan="1">0.954</td><td rowspan="1" colspan="1">2.44 &#x000b1; 2.10</td><td rowspan="1" colspan="1">2.31 &#x000b1; 2.41</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Fertilization rate (%) (Per cycle)</bold></td><td rowspan="1" colspan="1"> 0.458</td><td rowspan="1" colspan="1">62 &#x000b1; 27</td><td rowspan="1" colspan="1">58 &#x000b1; 30</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Clinical pregnancy rate (%) (Per cycle)</bold></td><td rowspan="1" colspan="1">0.389 </td><td rowspan="1" colspan="1">13.3%</td><td rowspan="1" colspan="1">10%</td></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr></tbody></table></table-wrap><p>There were no significant differences between
groups in the number of used gonadotropin ampoules,
the duration of stimulation, the number of
retrieved oocytes, fertilization rate and the number
of transferred embryos. The clinical pregnancy rate
(per cycle) was 10% (<xref rid="B6" ref-type="bibr">6</xref>) in group I and 13,3% (<xref rid="B8" ref-type="bibr">8</xref>)
in group II, which was statistically similar in both
groups (p=0.389), although there was a trend toward
a higher clinical pregnancy rate in the ultrashort agonist/
antagonist protocol.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The best stimulation protocol for poor responders
remains controversial. An adequate stimulation
protocol should lead to an acceptable rate of cancellation,
retrieve an adequate number of oocytes, obtain
good quality embryos, and eventually achieve
maximum pregnancy and live birth rates (<xref rid="B20" ref-type="bibr">20</xref>). Several
stimulation regimens have been proposed for
poor responders. Some have improved the ovarian
response to stimulation but none were able to
significantly improve the pregnancy rate (<xref rid="B21" ref-type="bibr">21</xref>). The
most common protocols for management of poor
responders are the microdose flare-up protocol
and antagonist protocol. The microdose flare-up
protocol benefits from the release of endogenous
gonadotropin in the early follicular phase of the
cycle through administration of a low dose GnRH
agonist to enhance response to ovarian stimulation.
However this approach may lead to a premature
LH surge and compromise the cycle, which in
turn can affect oocyte and embryo quality, in addition
to synchronization between the embryo and
endometrium (<xref rid="B19" ref-type="bibr">19</xref>). Addition of gonadotropin to an
ovarian stimulation protocol prevents premature
LH surge without suppression of early follicular
development (<xref rid="B22" ref-type="bibr">22</xref>).</p><p>In the present study, we compared the microdose
GnRH agonist flare-up and ultrashort GnRH agonist
that was combined with the fixed multidose
GnRH antagonist. According to our findings, poor
responders demonstrated similar outcomes. The
number of used gonadotropin ampoules, duration
of simulation, and the number of retrieved oocytes
were statistically similar in both groups. Fertilization
and pregnancy rates per cycles were similar
in both groups. Antagonist consumption in a poor
responder stimulation protocol is associated with
the possibility of decreasing the number of gonadotropin
ampoules used and reducing the duration
of stimulation. However Scott and Navot have
studied the microdose GnRH flare-up protocol for
low responder women in an ART protocol and reported
a lower cancellation rate, increased number
of retrieved oocytes, and higher pregnancy rates
in these patients (<xref rid="B23" ref-type="bibr">23</xref>). A number of previous studies
have evaluated the effect of a GnRH antagonist
in the management of poor responders and determined
that these protocols improved implantation
and pregnancy rates (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). The first study that
has compared an agonist-antagonist protocol with
the microdose flare-up protocol was reported by
Berger et al. (<xref rid="B26" ref-type="bibr">26</xref>). They showed that addition of antagonist to an agonist in the ovarian stimulation
protocol was associated with reduced gonadotropin
consumption and duration of stimulation. However,
as with our study, they have demonstrated that the
agonist-antagonist is not inferior to the microdose
flare-up protocol in poor responders (<xref rid="B26" ref-type="bibr">26</xref>). Erden et
al. in a pilot study demonstrated that the agonistantagonist
protocol compared to microdose flareup
was associated with higher peak estradiol levels,
more mature and fertilized oocytes, and higher
clinical pregnancies (<xref rid="B27" ref-type="bibr">27</xref>).</p><p>Orvieto et al. compared an ultrashort GnRH
agonist combined with a flexible multidose GnRH
antagonist and microdose flare-up administration
of GnRH. In contrast to our results, they found
higher numbers of mature oocytes and embryos
in the ultrashort GnRH agonist/ antagonist group.
Pregnancy rate was also significantly higher in this
group (<xref rid="B28" ref-type="bibr">28</xref>). In contrast to our study, they used a
flexible multidose GnRH antagonist and defined
poor responder as the retrieval of fewer than five
oocytes in the previous ART cycle.</p><p>The successful end-point of ART is to obtain a
live, healthy infant (<xref rid="B17" ref-type="bibr">17</xref>). Studies have shown similar
ART outcomes or only increased numbers of
retrieved oocytes and/or obtained embryos. They
could not recommend a unique protocol for increasing
live births in poor responders (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Although our findings showed no statistically
difference in clinical pregnancy rate and ART outcome
between these two protocols, however this
new protocol could possibly be considered as a future
ovarian stimulation protocol for poor responders.
Additional, large randomized prospective studies
are recommended to further evaluate the role of
agonist-antagonist in poor responder protocols.</p></sec></body><back><ack><p>We thank our colleagues and nurses at the Departments
of Obstetrics and Gynecology in Yazd
Research and Clinical Center for Infertility for their
support during this trial. This trial was supported
by internal funding from the Research and Clinical
Center for Infertility, Shahid Sadoughi University
of Medical Sciences, Yazd, Iran.The authors have
no conflicts of interest.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Velasco</surname><given-names>JA</given-names></name><name><surname>Isaza</surname><given-names>V</given-names></name><name><surname>Requena</surname><given-names>A</given-names></name><name><surname>Martinez-Salazar</surname><given-names>FJ</given-names></name><name><surname>Landazabal</surname><given-names>A</given-names></name><name><surname>Remohi</surname><given-names>J</given-names></name><etal/></person-group><article-title>High
doses of gonadotrophins combined with stop versus
non-stop protocol of GnRH analogue administration
in low responder IVF patients: a prospective,
randomized, controlled trial</article-title><source>Hum Reprod</source><year>2000</year><volume>15</volume><issue>11</issue><fpage>2292</fpage><lpage>2296</lpage><pub-id pub-id-type="pmid">11056121</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucuk</surname><given-names>T</given-names></name><name><surname>Kozinoglu</surname><given-names>H</given-names></name><name><surname>Kaba</surname><given-names>A</given-names></name></person-group><article-title>Growth hormone cotreatment
within a GnRH agonist long protocol in
patients with poor ovarian response: a prospective,
randomized, clinical trial</article-title><source>J Assist Reprod Genet</source><year>2008</year><volume>25</volume><issue>4</issue><fpage>123</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">18392675</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahrokh Tehraninejad</surname><given-names>E</given-names></name><name><surname>Fazel</surname><given-names>A</given-names></name><name><surname>Samiei</surname><given-names>A</given-names></name><name><surname>Rashidi</surname><given-names>B</given-names></name><name><surname>Kiani</surname><given-names>K</given-names></name></person-group><article-title>Flexible, Multi-dose GnRH Antagonist
versus Long GnRH Agonist Protocol in Poor
Responders: A Randomized Controlled Trial</article-title><source>Int J
Fertil Stril</source><year>2009</year><volume>2</volume><issue>4</issue><fpage>165</fpage><lpage>168</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surrey</surname><given-names>ES</given-names></name><name><surname>Schoolcraft</surname><given-names>WB</given-names></name></person-group><article-title>Evaluating strategies
for improving ovarian response of the poor
responder undergoing assisted reproductive techniques</article-title><source>Fertil Steril</source><year>2000</year><volume>73</volume><issue>4</issue><fpage>667</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">10731523</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tazeg&#x000fc;l</surname><given-names>A</given-names></name><name><surname>G&#x000f6;rkemli</surname><given-names>H</given-names></name><name><surname>&#x000d6;zdemir</surname><given-names>S</given-names></name><name><surname>Aktan</surname><given-names>TM</given-names></name></person-group><article-title>Comparison of multiple dose GnRH antagonist and
minidose long agonist protocols in poor responders
undergoing in vitro fertilization: a randomized
controlled trial</article-title><source>Arch Gynecol Obstet</source><year>2008</year><volume>278</volume><issue>5</issue><fpage>467</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">18335226</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarlatzis</surname><given-names>BC</given-names></name><name><surname>Zepiridis</surname><given-names>L</given-names></name><name><surname>Grimbizis</surname><given-names>G</given-names></name><name><surname>Bontis</surname><given-names>J</given-names></name></person-group><article-title>Clinical management of low ovarian response to
stimulation for IVF: a systematic review</article-title><source>Hum Reprod Update</source><year>2003</year><volume>9</volume><issue>1</issue><fpage>61</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">12638782</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahutte</surname><given-names>NG</given-names></name><name><surname>Arici</surname><given-names>A</given-names></name></person-group><article-title>Poor responders: does the
protocol make a difference?</article-title><source>Curr Opin Obstet
Gynecol</source><year>2002</year><volume>14</volume><issue>3</issue><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">12032382</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollenhoven</surname><given-names>B</given-names></name><name><surname>Osianlis</surname><given-names>T</given-names></name><name><surname>Catt</surname><given-names>J</given-names></name></person-group><article-title>Is there an ideal
stimulation regimen for IVF for poor responders and
does it change with age?</article-title><source>J Assist Reprod Genet</source><year>2008</year><volume>25</volume><issue>11-12</issue><fpage>523</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">18982442</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabregues</surname><given-names>F</given-names></name><name><surname>Penarrubia</surname><given-names>J</given-names></name><name><surname>Creus</surname><given-names>M</given-names></name><name><surname>Manau</surname><given-names>D</given-names></name><name><surname>Casals</surname><given-names>G</given-names></name><name><surname>Carmona</surname><given-names>F</given-names></name><etal/></person-group><article-title>Transdermal testosterone
may improve ovarian response to gonadotrophins
in low-responder IVF patients: a randomized,
clinical trial</article-title><source>Hum Reprod</source><year>2009</year><volume>24</volume><issue>2</issue><fpage>349</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">19054777</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goswami</surname><given-names>SK</given-names></name><name><surname>Das</surname><given-names>T</given-names></name><name><surname>Chattopadhyay</surname><given-names>R</given-names></name><name><surname>Sawhney</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>J</given-names></name><name><surname>Chaudhury</surname><given-names>K</given-names></name><etal/></person-group><article-title>A randomized singleblind
controlled trial of letrozole as a low-cost IVF
protocol in women with poor ovarian response: a
preliminary report</article-title><source>Hum Reprod</source><year>2004</year><volume>19</volume><issue>9</issue><fpage>2031</fpage><lpage>2035</lpage><pub-id pub-id-type="pmid">15217999</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demirol</surname><given-names>A</given-names></name><name><surname>Gurgan</surname><given-names>T</given-names></name></person-group><article-title>Comparison of microdose
flare-up and antagonist multiple-dose protocols for
poor-responder patients: a randomized study</article-title><source>Fertil
Steril</source><year>2009</year><volume>92</volume><issue>2</issue><fpage>481</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">18990368</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davar</surname><given-names>R</given-names></name><name><surname>Aflatoonian</surname><given-names>A</given-names></name><name><surname>Asgharnia</surname><given-names>M</given-names></name></person-group><article-title>Clinical Effects
of a Microdose GnRH Agonist Flare Regimen Administered to Poor Responders Undergoing ART
Cycles</article-title><source>Acta Medica Iranica</source><year>2009</year><volume>47</volume><issue>4</issue><fpage>263</fpage><lpage>267</lpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padilla</surname><given-names>SL</given-names></name><name><surname>Dugan</surname><given-names>K</given-names></name><name><surname>Maruschak</surname><given-names>V</given-names></name><name><surname>Shalika</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>RD</given-names></name></person-group><article-title>Use of the flare-up protocol with high dose human
follicle stimulating hormone and human menopausal
gonadotropins for in vitro fertilization in poor
responders</article-title><source>Fertil Steril</source><year>1996</year><volume>65</volume><issue>4</issue><fpage>796</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">8654641</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surrey E</surname><given-names>S</given-names></name></person-group><article-title>Management of the poor responder: the
role of GnRH agonists and antagonists</article-title><source>J Assist Reprod
Genet</source><year>2007</year><volume>24</volume><issue>12</issue><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">18046641</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diedrich</surname><given-names>K</given-names></name><name><surname>Diedrich</surname><given-names>C</given-names></name><name><surname>Santos</surname><given-names>E</given-names></name><name><surname>Zoll</surname><given-names>C</given-names></name><name><surname>Al-Hasani</surname><given-names>S</given-names></name><name><surname>Reissmann</surname><given-names>T</given-names></name><etal/></person-group><article-title>Suppression of the endogenous
luteinizing hormone surge by the gonadotrophin-
releasing hormone antagonist Cetrorelix
during ovarian stimulation</article-title><source>Hum Reprod</source><year>1994</year><volume>9</volume><issue>5</issue><fpage>788</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">7929723</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lainas</surname><given-names>TG</given-names></name><name><surname>Sfontouris</surname><given-names>IA</given-names></name><name><surname>Papanikolaou</surname><given-names>EG</given-names></name><name><surname>Zorzovilis</surname><given-names>JZ</given-names></name><name><surname>Petsas</surname><given-names>GK</given-names></name><name><surname>Lainas</surname><given-names>GT</given-names></name><etal/></person-group><article-title>Flexible
GnRH antagonist versus flare-up GnRH agonist
protocol in poor responders treated by IVF: a randomized
controlled trial</article-title><source>Hum Reprod</source><year>2008</year><volume>23</volume><issue>6</issue><fpage>1355</fpage><lpage>1358</lpage><pub-id pub-id-type="pmid">18403419</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandian</surname><given-names>Z</given-names></name><name><surname>McTavish</surname><given-names>AR</given-names></name><name><surname>Aucott</surname><given-names>L</given-names></name><name><surname>Hamilton</surname><given-names>MP</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name></person-group><article-title>Interventions for 'poor responders'
to controlled ovarian hyper stimulation (COH) in invitro
fertilisation (IVF)</article-title><source>Cochrane Data base Syst
Rev</source><year>2010</year><volume>1</volume><fpage>CD004379</fpage><lpage>CD004379</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akman</surname><given-names>MA</given-names></name><name><surname>Erden</surname><given-names>HF</given-names></name><name><surname>Tosun</surname><given-names>SB</given-names></name><name><surname>Bayazit</surname><given-names>N</given-names></name><name><surname>Aksoy</surname><given-names>E</given-names></name><name><surname>Bahceci</surname><given-names>M</given-names></name></person-group><article-title>Addition of GnRH antagonist in cycles
of poor responders undergoing IVF</article-title><source>Hum Reprod</source><year>2000</year><volume>15</volume><issue>10</issue><fpage>2145</fpage><lpage>2147</lpage><pub-id pub-id-type="pmid">11006188</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berker</surname><given-names>B</given-names></name><name><surname>Duvan</surname><given-names>C&#x00130;</given-names></name><name><surname>Kaya</surname><given-names>C</given-names></name><name><surname>Ayta&#x000e7;</surname><given-names>R</given-names></name><name><surname>&#x0015e;at&#x00131;ro&#x0011f;lu</surname><given-names>H</given-names></name></person-group><article-title>Comparison of the ultrashort gonadotropin-releasing
hormone agonist-antagonist protocol with
microdose flare-up protocol in poor responders: a
preliminary study</article-title><source>J Turkish German Gynecol Assoc</source><year>2010</year><volume>11</volume><issue>4</issue><fpage>187</fpage><lpage>193</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griesinger</surname><given-names>G</given-names></name><name><surname>Diedrich</surname><given-names>K</given-names></name><name><surname>Tarlatzis</surname><given-names>BC</given-names></name><name><surname>Kolibianakis</surname><given-names>EM</given-names></name></person-group><article-title>GnRH-antagonists in ovarian stimulation
for IVF in patients with poor response to gonadotrophins,
polycystic ovary syndrome, and risk of
ovarian hyperstimulation: a meta-analysis</article-title><source>Reprod
Biomed Online</source><year>2006</year><volume>13</volume><issue>5</issue><fpage>628</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">17169171</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahraman</surname><given-names>K</given-names></name><name><surname>Berker</surname><given-names>B</given-names></name><name><surname>Atabekoglu</surname><given-names>CS</given-names></name><name><surname>Sonmezer</surname><given-names>M</given-names></name><name><surname>Cetinkaya</surname><given-names>E</given-names></name><name><surname>Aytac</surname><given-names>R</given-names></name><etal/></person-group><article-title>Microdose gonadotropin-
releasing hormone agonist flare-up protocol
versus multiple dose gonadotropin-releasing hormone
antagonist protocol in poor responders undergoing
intracytoplasmic sperm injection-embryo
transfer cycle</article-title><source>Fertil Steril</source><year>2009</year><volume>91</volume><issue>6</issue><fpage>2437</fpage><lpage>2444</lpage><pub-id pub-id-type="pmid">18555238</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surrey</surname><given-names>ES</given-names></name></person-group><article-title>Management of the poor responder: the
role of GnRH agonists and antagonists</article-title><source>J Assist
Reprod Genet</source><year>2007</year><volume>24</volume><issue>12</issue><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">18046641</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>RT</given-names></name><name><surname>Navot</surname><given-names>D</given-names></name></person-group><article-title>Enhancement of ovarian responsiveness
with microdoses of gonadotropinreleasing
hormone agonist during ovulation induction
for in vitro fertilization</article-title><source>Fertil Steril</source><year>1994</year><volume>61</volume><issue>5</issue><fpage>880</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">8174725</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akman</surname><given-names>MA</given-names></name><name><surname>Erden</surname><given-names>HF</given-names></name><name><surname>Tosun</surname><given-names>SB</given-names></name><name><surname>Bayazit</surname><given-names>N</given-names></name><name><surname>Aksoy</surname><given-names>E</given-names></name><name><surname>Bahceci</surname><given-names>M</given-names></name></person-group><article-title>Addition of GnRH antagonist in cycles
of poor responders undergoing IVF</article-title><source>Hum Reprod</source><year>2000</year><volume>15</volume><issue>10</issue><fpage>2145</fpage><lpage>2147</lpage><pub-id pub-id-type="pmid">11006188</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craft</surname><given-names>I</given-names></name><name><surname>Gorgy</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>J</given-names></name><name><surname>Menon</surname><given-names>D</given-names></name><name><surname>Podsiadly</surname><given-names>B</given-names></name></person-group><article-title>Will
GnRH antagonists provide new hope for patients
considered &#x0201c;difficult responders&#x0201d; to GnRH agonist
protocols?</article-title><source>Hum Reprod</source><year>1999</year><volume>14</volume><issue>12</issue><fpage>2959</fpage><lpage>2962</lpage><pub-id pub-id-type="pmid">10601078</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>BM</given-names></name><name><surname>Ezcurra</surname><given-names>D</given-names></name><name><surname>Alper</surname><given-names>MM</given-names></name></person-group><article-title>The agonistantagonist
protocol: anovel protocol for treating
the poor responder</article-title><source>Fertil steril</source><year>2004</year><volume>82</volume><issue>Suppl 2</issue><fpage>S126</fpage><lpage>S126</lpage></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erden</surname><given-names>HF</given-names></name><name><surname>Akman</surname><given-names>MA</given-names></name><name><surname>Bayazit</surname><given-names>N</given-names></name><name><surname>Bahceci</surname><given-names>M</given-names></name></person-group><article-title>Efficacy
of a new agonist-antagonist protocol compared
to mcrodose flare-up in poor responder IVF patients</article-title><source>Fertil steril</source><year>2005</year><volume>84</volume><issue>Suppl 1</issue><fpage>S128</fpage><lpage>S129</lpage></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orvieto</surname><given-names>R</given-names></name><name><surname>Kruchkovich</surname><given-names>J</given-names></name><name><surname>Rabinson</surname><given-names>J</given-names></name><name><surname>Zohav</surname><given-names>E</given-names></name><name><surname>Anteby</surname><given-names>EY</given-names></name><name><surname>Meltcer</surname><given-names>S</given-names></name><etal/></person-group><article-title>Ultrashort gonadotropin-releasing
hormone agonist combined with flexible multidose
gonadotropin-releasing hormone antagonist for poor
responders in in vitro fertilization/embryo transfer
programs</article-title><source>Fertil Steril</source><year>2008</year><volume>90</volume><issue>1</issue><fpage>228</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">17681292</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolettos</surname><given-names>N</given-names></name><name><surname>Al-Hasani</surname><given-names>S</given-names></name><name><surname>Felberbaum</surname><given-names>R</given-names></name><name><surname>Demirel</surname><given-names>LC</given-names></name><name><surname>Kupker</surname><given-names>W</given-names></name><name><surname>Montzka</surname><given-names>P</given-names></name><etal/></person-group><article-title>Gonadotropin-releasing
hormone antagonist protocol: a novel method
of ovarian stimulation in poor responders</article-title><source>Eur J
Obstet Reprod Biol</source><year>2001</year><volume>97</volume><issue>2</issue><fpage>202</fpage><lpage>207</lpage></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akman</surname><given-names>MA</given-names></name><name><surname>Erden</surname><given-names>HF</given-names></name><name><surname>Tosun</surname><given-names>SB</given-names></name><name><surname>Bayazit</surname><given-names>N</given-names></name><name><surname>Aksoy</surname><given-names>E</given-names></name><name><surname>Bahceci</surname><given-names>M</given-names></name></person-group><article-title>Comparison of agonistic flare-upprotocol
and antagonistic multiple dose protocol
in ovarian stimulation of poor responders: results
of a prospective randomized trial</article-title><source>Hum Reprod</source><year>2001</year><volume>16</volume><issue>5</issue><fpage>868</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">11331630</pub-id></element-citation></ref></ref-list></back></article>